Drug Database
Back to search

Iceland· IS-EU/1/22/1642/001

Orgovyx

A relugolix product containing relugolixum inn, registered in Iceland by Accord Healthcare S.L.U.. The same ATC class is registered in 15 of our 19 countries.

ATC L02BX04

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedOrgovyxATCL02BX04REGISTER NO.IS-EU/1/22/1642/001PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about relugolixum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Relugolix is registered in 15 of 19 countries.

Countries holding a registration under ATC L02BX04 (relugolix), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 10 of them publish a price we can compare per daily dose
Search relugolix products by name

Relugolix · ATC L02BX04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of relugolix costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), the median price runs from $3.40 in France to $9.83 in Italy — a ×2.9 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Relugolix · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • IT Italy$9.83
  • ES Spain$7.69
  • CH Switzerland$6.03
  • FR France$3.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Relugolixum INN
Manufacturer
Accord Healthcare S.L.U.
Country
Iceland (IS)
ATC code
L02BX04
ATC class
Relugolix
Defined daily dose
0.12 g, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    555034
    30 stk x1 glas
    ISK 36350

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

168 interactions on record for relugolix.

Graded by severity as the source publishes them — 52 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check relugolix against other medicinesHow interaction checks work

Relugolix · interactions on record

168 records

  • 52 severe
  • 101 moderate
  • 15 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • FidaxomicinA07AA12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Relugolix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All relugolix products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Orgovyx
  • Norway · Orgovyx

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5857acec-00bd-4ba2-a381-d6503daf9866
GET /v1/drugs/5857acec-00bd-4ba2-a381-d6503daf9866?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "L02BX04",
  "marketed": true,
  "strength": "120 mg",
  "ma_number": "EU/1/22/1642/001",
  "substance": "Relugolixum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í þvagfæraskurðlækningum og krabbameinslækningum.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "44680"
}
API referenceMCP serverPlans

See everything about relugolix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console